Soft-tissue sarcomas (STS) are a group of rare mesenchymal tumors that constitutes ∼1% of all solid tumors. It remains a rare tumor which lacks effective treatment options. Precision oncology may be of interest in this regard by identifying potential targets for emerging novel therapies. Neurotrophic receptor tyrosine kinase (NTRK) fusions are rare oncogenic driver mutations found in a broad range of common and rare tumor subtypes including STS. The recent approvals of NTRK inhibitors (larotrectinib and entrectinib) represent new therapeutic options in the drug armamentarium especially valuable in advanced STS given the paucity of treatment options and the generally poor prognosis of these tumors. We review the methods used to detect NTRK fusions in STS with focus on incidence, diagnosis and management of these rare and intriguing oncogenic targets.

中文翻译：

---

TRK抑制软组织肉瘤：全面审查。

软组织肉瘤（STS）是一组罕见的间质瘤，约占所有实体瘤的1％。它仍然是一种罕见的肿瘤，缺乏有效的治疗选择。在这方面，通过确定新兴疗法的潜在靶点，精密肿瘤学可能会引起人们的兴趣。神经营养受体酪氨酸激酶（NTRK）融合是罕见的致癌驱动突变，存在于包括STS在内的多种常见和罕见肿瘤亚型中。NTRK抑制剂（larotrectinib和entrectinib）的最新批准代表了药物库中的新治疗选择，由于治疗选择的不足以及这些肿瘤的预后普遍较差，因此在晚期STS中特别有价值。我们回顾了用于检测STS中NTRK融合的方法，重点是发病率，